Rapamycin passes the torch: a new generation of mTOR inhibitors
By Don Benjamin, M. Colombi, C. Moroni, Michael N. Hall. Nature reviews. Drug discovery, 2011
979 citations recorded by the source corpus.
Subfields: Molecular Biology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/87ecf133d31907105b5a402f20fddd54b8b54a46
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- R. Shaw
- David M. Sabatini
- Michael N. Hall
- R. Loewith
- Michael Pollak
- Nahum Sonenberg
- W. Oppliger
- Eyal Gottlieb
In Pathology and Forensic Medicine
Citations in the corpus
- Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates (2015, background): “…use of this compound and its derivatives in animal models of cancer and other diseases. mTOR inhibitors are being widely tested in clinical trials for oncology, and rapamycin analogs are the approved standard of care for advanced renal cell carcinoma and other solid tumors (Benjamin et al., 2011).”
- mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. (2013, background): “…may induce a state of ‘‘metabolic dormancy’’ in cancer cells, which would predict a cytostatic rather than cytotoxic effect of asTORi in the clinic (Benjamin et al., 2011). mTOR is a multifaceted kinase that employs a number of effectors to exert its biological functions (Laplante and…”
- Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease (2023, background): “18 25 The stimulation of the mTOR cascade has been displayed to increase tumor growth through the regulation of glycolysis, angiogenesis, growth factor receptor pathway, lipid metabolism, and autophagy.”
- mTOR: a pharmacologic target for autophagy regulation. (2015, neutral): “84).”
- Target of Rapamycin (TOR) in Nutrient Signaling and Growth Control (2011, background): “The story of the TOR-signaling network begins with a remarkable drug, rapamycin (Abraham and Wiederrecht 1996; Benjamin et al. 2011).”
- Glutaminolysis activates Rag-mTORC1 signaling. (2012, background): “The glutaminolysis inhibitor DON has been investigated as an anticancer drug, but was discarded due to toxic side effects (Souba, 1993). mTOR inhibition is a validated anticancer strategy (Benjamin et al., 2011).”
- The Transcription Factor TFEB Links mTORC1 Signaling to Transcriptional Control of Lysosome Homeostasis (2012, positive): “Rapamycin, an allosteric mTORC1 inhibitor (29), had minimal effects on TFEB localization (Fig.”